CN111996153A - Bifidobacterium breve and application thereof - Google Patents
Bifidobacterium breve and application thereof Download PDFInfo
- Publication number
- CN111996153A CN111996153A CN202010984015.1A CN202010984015A CN111996153A CN 111996153 A CN111996153 A CN 111996153A CN 202010984015 A CN202010984015 A CN 202010984015A CN 111996153 A CN111996153 A CN 111996153A
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium breve
- mice
- percent
- group
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000186012 Bifidobacterium breve Species 0.000 title claims abstract description 60
- 210000004347 intestinal mucosa Anatomy 0.000 claims abstract description 12
- 238000004321 preservation Methods 0.000 claims abstract description 9
- 206010067125 Liver injury Diseases 0.000 claims abstract description 7
- 231100000753 hepatic injury Toxicity 0.000 claims abstract description 6
- 241000699670 Mus sp. Species 0.000 claims description 57
- 206010010774 Constipation Diseases 0.000 claims description 19
- 230000006378 damage Effects 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 230000036541 health Effects 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 208000014674 injury Diseases 0.000 claims description 11
- 208000027418 Wounds and injury Diseases 0.000 claims description 10
- 230000000968 intestinal effect Effects 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000001888 Peptone Substances 0.000 claims description 3
- 108010080698 Peptones Proteins 0.000 claims description 3
- 235000019319 peptone Nutrition 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 2
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 229940040526 anhydrous sodium acetate Drugs 0.000 claims description 2
- 235000020299 breve Nutrition 0.000 claims description 2
- 229940041514 candida albicans extract Drugs 0.000 claims description 2
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 2
- ISPYRSDWRDQNSW-UHFFFAOYSA-L manganese(II) sulfate monohydrate Chemical compound O.[Mn+2].[O-]S([O-])(=O)=O ISPYRSDWRDQNSW-UHFFFAOYSA-L 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 239000012138 yeast extract Substances 0.000 claims description 2
- 230000013872 defecation Effects 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 16
- 210000004185 liver Anatomy 0.000 abstract description 15
- 208000008589 Obesity Diseases 0.000 abstract description 2
- 235000020824 obesity Nutrition 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 230000037396 body weight Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 240000001929 Lactobacillus brevis Species 0.000 description 13
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 13
- 210000001072 colon Anatomy 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 7
- 235000013339 cereals Nutrition 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102000003929 Transaminases Human genes 0.000 description 4
- 108090000340 Transaminases Proteins 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 238000003794 Gram staining Methods 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- -1 compound diphenoxylate Chemical class 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229960004192 diphenoxylate Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- 235000020927 12-h fasting Nutrition 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 206010038084 Rectocele Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005289 dietary characteristics Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- XJCPMUIIBDVFDM-UHFFFAOYSA-M nile blue A Chemical compound [Cl-].C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4[O+]=C3C=C(N)C2=C1 XJCPMUIIBDVFDM-UHFFFAOYSA-M 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000007084 physiological dysfunction Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002563 stool test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000020990 white meat Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention also provides Bifidobacterium breve (Bifidobacterium breve) TR103 which is preserved in China center for type culture collection with the preservation number of CCTCC NO: m2018728, the preservation address is Wuhan university in Wuhan city of Hubei province of the people's republic of China, and the preservation date is 10 months and 31 days in 2018. The bifidobacterium breve TR103 provided by the invention is derived from the elderly with long life, and has the effects of protecting intestinal mucosa, protecting liver, avoiding liver injury, regulating defecation frequency and relieving obesity.
Description
Technical Field
The invention belongs to the field of microorganisms, and particularly relates to bifidobacterium breve and application of the strain.
Background
The factors causing the damage of the intestinal mucosa are mainly serious trauma, serious infection, burn, shock, acute pancreatitis and the damage of the intestinal mucosa barrier of other critical patients, and the latter can aggravate the conditions of various primary diseases, and the two are mutually promoted and cause and effect. The damage of chemotherapy drugs, abdominal dialysis, bacterial peritonitis, inflammatory bowel disease and other diseases to the intestinal mucosa is the most common, and the damage of the intestinal mucosa barrier can cause bacterial displacement, so that pathogenic bacteria parasitic on the large intestine can be displaced to the small intestine (transverse displacement), can cross the intestinal mucosa to enter mesenteric lymph nodes and portal veins and then enter systemic circulation (longitudinal displacement), and can cause serious systemic physiological dysfunction. Especially, the massive propagation of intestinal bacteria causes excessive toxin to enter portal vein and liver, once the capability of liver for removing toxin is reduced, endotoxemia occurs, and endotoxin can not only directly damage important organs, but also activate complement and coagulation mechanisms, so that respiratory distress syndrome and disseminated intravascular coagulation occur, and even multiple organ failure occurs. At present, the varieties of medicines for treating the intestinal mucosa injury disease are few, the curative effect of the existing western medicines for clinically treating the intestinal mucosa injury disease is limited, the western medicines have large side effect on liver and kidney, cannot be used for a long time, and are unfavorable for or have injury to the liver and kidney of a patient. The Chinese medicine has relatively few varieties, single treatment function and unobvious short-term curative effect.
The hazards of alcohol to the human body are well known. Excessive drinking can cause damage to the digestive system, circulatory system, etc., manifested as loss of control of mood, disturbance of consciousness, discomfort of digestive tract, and even death. Liver diseases such as alcoholic fatty liver, alcoholic hepatitis, alcoholic cirrhosis and the like caused by long-term drinking. The number of alcoholic liver patients in China is nearly hundred million, and the incidence rate is in an increasing trend every year. The long-term drinking can cause the myocardial cell membrane damage, the organelle dysfunction, the internal environment calcium ion unbalance and the protein contraction dysfunction to cause alcoholic heart disease. How to maintain the physical health of the drinkers is always a subject of high attention in the medical and social circles.
Constipation is a common symptom, which refers to decreased stool frequency and/or difficulty in stool drying, and generally no defecation occurs for more than two days, indicating that constipation exists. According to statistics, the number of constipation patients in China is more than 30%, women are more than 4 times of men, and the incidence rate of constipation patients increases with the increase of age. Modern scientific research shows that the excrement contains up to 796 toxic substances such as indole, hydrogen sulfide, methane, phenol, ammonia and the like, and the bacteria, the toxic substances and metabolic wastes can be discharged out of the body in time by people who defecate once every day. If defecation time exceeds 48 hours, virulence is multiplied. Patients with long-term constipation are easy to cause diseases such as hemorrhoids, anal fissure, rectocele and the like; the defecation force of patients suffering from heart disease and hypertension can induce stroke, myocardial infarction and cerebral hemorrhage, and even can cause life accidents; constipation also plays an important role in the development of diseases such as colon cancer (data indicate that about 10% of people with severe constipation suffer from colon cancer), hepatic encephalopathy, breast diseases, and alzheimer's disease. Therefore, the constipation can be prevented, treated reasonably in time, serious consequences and social burden caused by the constipation can be greatly reduced, and huge consumer groups of patients can strongly stimulate the constipation market to continuously expand. At present, many drugs can be used for treating constipation, but most drugs are not suitable for patients with chronic constipation and are not suitable for long-term use.
The increasing awareness of the relationship between diet and health has led to an increasing demand for products that enhance health in addition to providing basic nutrition. There are studies that show that ingestion of probiotics is beneficial to maintain a delicate microbial balance in the body. It is well known that this balance promotes the health of the intestine and enhances the immune system and other physiological functions, thereby becoming a key factor in overall improvement of human health.
Disclosure of Invention
The purpose of the invention is as follows: in order to ensure the health of people, the invention provides bifidobacterium breve.
The technical scheme is as follows: the technical scheme adopted by the invention is as follows:
bifidobacterium breve (Bifidobacterium breve) TR103, which is preserved in China center for type culture Collection with the preservation number of CCTCC NO: m2018728, the preservation address is Wuhan university in Wuhan city of Hubei province of the people's republic of China, and the preservation date is 10 months and 31 days in 2018.
Bifidobacterium breve (b) as described aboveBifidobacterium breve) The large-scale fermentation method of TR103 comprises the following steps:
the components are as follows: aqueous solution, wherein, 2 percent of yeast extract, 1 percent of soybean peptone, 0.5 percent of anhydrous sodium acetate, 0.2 percent of dipotassium phosphate, 0.2 percent of diammonium hydrogen citrate and 800.1 percent of tween-800 are sterilized for 20 minutes at 121 ℃;
and (2) component: an aqueous solution, wherein the glucose anhydrous is 2.3%, the galacto-oligosaccharide is 0.4%, the anhydrous magnesium sulfate is 0.025%, the manganese sulfate monohydrate is 0.02%, and the solution is sterilized at 115 ℃ for 20 minutes;
and (3) component: an aqueous solution, wherein, L-cysteine hydrochloride is 0.1 percent, and the sterilization kettle is sterilized for 20 minutes at the temperature of 121 ℃;
mixing component 1 cooled to below 40 deg.C and component 2 cooled to below 40 deg.C, and adjusting pH to 7.1; inoculating; then adding the component 3; culturing at constant temperature of 37 ℃.
The invention also provides bifidobacterium breve (b)Bifidobacterium breve) Application of TR103 in preparing medicine or health product for treating/preventing intestinal mucosa injury.
The invention also provides bifidobacterium breve (b)Bifidobacterium breve) Application of TR103 in preparing medicine or health product for preventing and/or treating liver injury caused by alcohol.
The invention also provides bifidobacterium breve (b)Bifidobacterium breve) Application of TR103 in preparing medicine or health product for preventing and/or treating constipation.
The invention also provides a pharmaceutical composition, which comprises bifidobacterium breve (Bifidobacterium: (B))Bifidobacterium breve) TR103, further comprising at least one pharmaceutically acceptable carrier, diluent, excipient or adjuvant.
Preferably, the pharmaceutical composition is a medicine or health-care product for treating/preventing intestinal mucosa damage of mice, preventing and/or treating liver damage caused by alcohol and preventing and/or treating constipation; bifidobacterium breve: (A), (B)Bifidobacterium breve) TR103 dose is (0.3-2.0). times.1010CFU/g。
Has the advantages that: the bifidobacterium breve TR103 provided by the invention is derived from the elderly with long life, and has the effects of protecting intestinal mucosa, protecting liver, avoiding liver injury, regulating defecation frequency and relieving obesity.
Drawings
FIG. 1 is a gram-stained optical micrograph of Bifidobacterium breve TR 103.
Fig. 2 is a biological phylogenetic tree diagram of bifidobacterium breve TR 103.
FIG. 3 is a photograph of the colon of each group of mice taken out after the groups of mice were dissected.
FIG. 4 is a graph showing the daily body weight of each group of mice after molding.
FIG. 5 is a graph showing the body weight change of mice after drinking alcohol and feeding stomach with Lactobacillus brevis TR 103.
FIG. 6 is a graph of the effect of Lactobacillus brevis TR103 on serum ALT in mice.
FIG. 7 is a graph showing the effect of Lactobacillus brevis TR103 on mouse serum AST.
Detailed Description
The invention is further described below with reference to the accompanying drawings.
Example 1 isolation, purification and characterization of the strains
1. Bacterial species and culture medium and culture conditions
(1) Bacterial source
New bifidobacterium breve is obtained by separating and screening strains in the body of one hundred years old.
Host health and dietary characteristics: the centenarian was able to move freely, had a good mental status and a normal body mass index. The daily diet mainly comprises coarse cereals and white meat, and the amount of Chinese liquor is about 50ml per day.
(2) Culture medium
Enrichment culture medium: 5g/L yeast powder, 10g/L peptone and 2.5g/L NaCl;
plate culture medium: 20g/L glucose, 2g/L (NH)4)2SO4,13.3g/L KH2PO4,1.2g/L MgSO4 .7H2O, 1.7g/L citric acid, 1.7g/L microelement solution, 15g/L agar and 0.5 mu g/mL Nile blue A.
2. Isolation and characterization of strains
(1) Isolation of the Strain
Taking about 0.2g sample, adding 1ml MRS culture medium, vortex and shake for 1min, sequentially diluting 10 times to 10-6, and coating 200 μ L of each diluted concentration on a coating containing 1% CaCO3Culturing in 37 deg.C anaerobic jar for 48h on MRS culture medium, selecting single colony on the plate, streaking and purifying on MRS solid culture medium, and culturing in 37 deg.C anaerobic jar for 48h to obtain pure colony.
(2) Identification of strains
Cell morphology:
short, fine or coarse cells, usually corynebacteria, with or without bifurcations. Particles are sometimes visible with gram staining. Cells self-agglutinate in saline. The colony is convex to pad, the surface is smooth or wave-curved, the whole edge is 2-3mm in diameter, and the quality is soft. Strains in the presence of CaCO3The diameter of the colony on the MRS culture medium is 2-3mm, the colony is white and convex, a calcium dissolving ring is arranged, and the surface is smooth or curvelling.
Biolog gram negative test:
gram-positive bacteria, cells are rod-shaped, and one end is sometimes bifurcated; gram staining characteristics of the cells are shown in FIG. 1.
Determination of 16SrRNA sequence:
the published 16S universal primers were used, and the primer sequences were:
S4-1:5’-ATAATGCGGCCGCACGGGCGGTGTGTRC-3’;
S4-2:5’-TAATAGCGGCCGCAGCMGCCGCGGTAATWC-3’。
amplifying and sequencing the 16SrDNA gene sequence of the strain TR103, sequencing the PCR amplification product by Huada Gene Co., Ltd, and sequencing the 16Sr of the strain TR103The nucleotide sequence of the DNA is sequence 1 in the sequence table; after 16SrDNA gene comparison, the gene is compared with that in GenebankBifidobacterium breveThe strain comparison similarity rate reaches 100 percent; combining with the identification of a microbial system, wherein TR103 is a strain of Bifidobacterium breve and is named as Bifidobacterium breve TR 103; the 16SrDNA of the Bifidobacterium breve TR103 is shown in SEQ ID NO.1, and the biological evolutionary tree is shown in FIG. 2.
Example 2 Effect of Bifidobacterium breve TR103 on relieving intestinal mucosal injury in mice and mechanism research thereof
1. Establishment and grouping of acute ulcerative colitis mouse model
60 male BALB/c mice were randomly divided into 5 groups: normal, model and TR103 low, medium and high dose groups, 12 per group.
From the first day of experiment, the normal group and the model group are administered with sterile physiological saline for intragastric administration, and TR103 low, medium and high dose groups are respectively administered with the concentration of 1 × 106、1×108、1×1010And (3) gavage of the bacterial solution of the TR103 cfu/mL, wherein each mouse is gavaged once a day, 0.2mL of the liquid is taken each time, and the gavage lasts for 14 days.
From the 8 th day of the test, according to the method of Murthy and the like, the distilled water drunk by the mice of the model group and the TR103 low, medium and high dose group is changed into 2.5% DSS solution, the experimental colitis model is caused by freely drinking for 7 days, the weight, the stool character and the occult blood condition of the mice are observed and recorded every day during the molding period, and the normal group drinks the distilled water.
2. Observation and determination of growth status of colitis mice
The body weights of the mice were measured and recorded every day after the model was made, and the average body weight of each group of mice after the model was made was calculated and the change was recorded.
3. Gross condition and length change of mouse colon
On the 15 th day of the experiment, the mouse was sacrificed by dislocation of cervical vertebrae, the colon was separated, and the general change of the colon was observed in each group of mice, and the length of the colon was measured from the junction of the small intestine and the cecum to the anus.
The pathological changes of the colons of all groups of mice are observed and recorded on the same day when the mice are sacrificed, the colons of all groups of mice taken out after dissection are shown in figure 3, and the colons of the normal group of mice are found to be 10.48 +/-0.74 cm in length, the intestinal tissues are intact and the excrement in the intestinal cavity is formed; the colon length of the model group and the colon length of the mouse with the low dose of the Bifidobacterium breve TR103 are respectively 7.33 +/-1.32 cm and 7.99 +/-1.29 cm, the intestinal wall is thinned, unformed stool can be seen in the intestinal cavity, and dark red bloody stool is formed in part of the intestinal cavity of the mouse; the colon lengths of the mice in the high dose group and the middle dose group of the Bifidobacterium breve TR103 are 8.76 +/-0.63 cm and 8.06 +/-0.94 cm respectively, the intestinal intracavity bleeding of the two groups is rare, and the feces are basically formed, wherein the colon state of the mice in the high dose group of the Bifidobacterium breve TR103 is closest to that of the normal group. Each group of bifidobacterium breve TR103 was significantly different from the model group (P < 0.05).
The daily body weights of the mice in each group after molding are shown in fig. 4, and the results show that: starting from mice freely drinking 2.5% DSS aqueous solution, the model group mice showed decreased food intake and weight loss with time, and gradually increased. The growth condition of the mice of the Bifidobacterium breve TR103 group is gradually improved along with the increase of the concentration of the gavage liquid, the weight is reduced slowly compared with the weight of the mice of the model group, and the symptoms of diarrhea and hematochezia are also reduced to different degrees, wherein the group of the Bifidobacterium breve TR103 high dose shows significant difference. The weight of the mice in the normal group is in a continuous rising trend, and the activity is normal.
Example 3 study of Lactobacillus brevis TR103 on reduction of chronic alcoholic liver injury in mice
1. Grouping and handling of test animals
Feeding 5 ICR mice in one cage, freely drinking water and eating, regularly replacing padding, keeping clean and dry in the mouse cage, adaptively feeding for 1 week, randomly dividing the mice into 4 groups, and feeding 15 mice in each group; respectively blank control group, alcohol injury group, and Bifidobacterium breve TR103 low dose test group (1.0 × 10)8CFU/mL), Bifidobacterium breve TR103 high dose test group (1.0X 10)10CFU/mL)。
The test is started for 0-2 weeks, and the control group and the alcohol-damaged group of mice are correspondingly given with 0.2 mL/(d) of intragastric normal saline, and the Bifidobacterium breve TR103 groups are respectively given with 0.2 mL/(d) of intragastric lactobacillus. On the basis of the intragastric administration mode of the first two weeks from the 3 rd week, after half an hour, the intragastric administration of 0.15 mL/(d) of physiological saline is added once for the control group, and the intragastric administration of 0.15 mL/(d) of 50% ethanol solution is added once for the alcohol injury group and the test group, and the duration is 1 week. The stomach is irrigated after half an hour for 4-6 weeks, and the volume of the physiological saline and the alcohol solution is increased to 0.20 mL/(d). And (3) after the stomach is perfused for 7-12 weeks and half an hour later, the volume of the physiological saline and the alcohol solution is increased to 0.25 mL/(d only).
2. Detection index of test animal
2.1 mouse body weight and apparent characteristics
During the test, the padding is replaced at regular time, and the padding is kept dry and the drinking water is sufficient. The food intake and water intake were recorded daily, the apparent characteristic changes of the mice were closely observed, and the body weights of the mice in each group were regularly weighed every week.
2.2 sample processing method
Serum: after fasting for 12h in mice at the end of 12 weeks of the experiment, the final body weight was weighed, blood was collected, and the mice were euthanized. Standing the blood at room temperature for 1h, centrifuging (3500 r/min, 15 min), collecting supernatant, and storing at-80 deg.C. The Total Cholesterol (TC), total Triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) contents of mouse serum were measured using a fully automated biochemical analyzer. The kit method is used for measuring the content of glutamic acid Aminotransferase (ALT) and aspartic acid Aminotransferase (AST) in the serum of the mouse.
Organ tissues: the visceral tissues were harvested quickly after sacrifice. The organ tissues include brain, liver, kidney, spleen and small intestine. Weighing each tissue, placing in liquid nitrogen for quick freezing, and storing at-80 deg.C to be tested. Organ index (liver, spleen, kidney) (%) = visceral weight/rat body weight × 100%.
2.3 preparation of mouse liver homogenate
After dissecting the mouse, the right lobe tissue of the mouse liver was rapidly picked up, weighed, cut into pieces, mixed with 9 times volume of pre-cooled physiological saline, and fully ground into 10% liver tissue homogenate. After the 10% liver homogenate is prepared, centrifuging for 15min at 3000r/min, discarding the precipitate and leaving the supernatant for later use, and freezing the liver homogenate at-80 ℃.
2.4 measurement of liver homogenate index in mouse
The concentration of the contents of glutamic acid Aminotransferase (ALT) and aspartic acid Aminotransferase (AST) in the liver homogenate of the mouse is determined strictly according to the specific operation steps of the corresponding kit instructions.
3. Results of the experiment
3.1 Effect of Lactobacillus brevis TR103 on mouse body weight
FIG. 5 shows the trend of body weight change after intragastric administration of Bifidobacterium breve TR103 to mice receiving alcohol. In the adaptation period of 0-2 weeks, the body weight of each group of mice shows a trend of obvious increase; the test substance was gavaged in each group from week 3, and the body weight of the mice in the control group was continuously increased and the body weight of the mice in the alcohol-damaged group was decreased (P < 0.05). The weight of the mice perfused with Lactobacillus brevis TR103 was higher than that of the alcohol-injured group, and there was no significant difference between the high-dose group and the low-dose group (P > 0.05).
3.2 Effect of Lactobacillus brevis TR103 on mouse serum ALT and AST
As shown in FIG. 6, the serum AST level of the alcohol-damaged mice was increased by 11.8% (P > 0.05) compared to the control group. After the administration of bifidobacterium breve TR103, the AST level of each group has no significant change compared with the alcohol-damaged group (P is more than 0.05). The AST level of mice in the low-dose group is obviously increased compared with that in the control group (P < 0.05), and the Lactobacillus brevis TR103 high-dose group has no obvious difference with the control group (P > 0.05).
Figure 7 compares the serum ALT activity levels of the mice in each group, the alcohol-injured group and the lactobacillus brevis TR103 dose group were not significantly different from the control group (P > 0.05).
The test results show that the serum AST level of the alcohol injury group is increased due to the intragastric alcohol, which indicates that the alcohol already causes the liver cell injury. After the action of the bifidobacterium breve TR103, the difference between the high-dose group and the control group is not obvious (P is more than 0.05), which indicates that the bifidobacterium breve TR103 has certain capacity of relieving cell damage.
Example 4 study of the Effect of Lactobacillus brevis TR103 on relieving constipation in mice
1. Grouping and processing of laboratory animals
The experimental strains were assigned 3 dose groups, blank groups and model groups. Air conditionerThe weight fraction of the skim milk for intragastric administration of the white group and the model group of mice is 10 percent and is 0.1 mL/(kg. d) (based on the weight of the body); lactobacillus brevis TR103 low-dose, medium-dose and high-dose mice are respectively gavaged by 1 × 106、1×108、1×1010CFU/mL of bacterial suspension 0.1 mL/(kg. d) (based on body mass). Once a day, free access to food during the trial, and body mass changes were recorded for each group of mice.
2. Stool test of mice
After the test sample was given for 7d, each group of mice was fasted for 16h without water deprivation. The mice of the model group and 3 dose groups were gavaged with compound diphenoxylate (10 mg/kg) and the blank group was given distilled water. 2X 106、2×108、2×1010The TR103 bacterial suspension of CFU/mL and the ink are mixed in equal volume, after the compound diphenoxylate is administered for 0.5h, the blank group and the model group are perfused with the ink of 0.1mL/kg (by a physique amount), the low, medium and high dose groups and the control group are administered with the ink containing the tested sample of 0.1mL/kg (by a physique amount), and the animals are all raised in a single cage and fed with normal drinking water. Starting from the gastric lavage ink, recording the first grain defecation time of each animal, the number of black grains in 5h and the quality of the black grains. The collected feces were dried at 105 ℃ until the mass was constant, and the moisture content of the feces was calculated according to the formula (1).
TABLE 1
The study was performed under normal physiological conditions in mice. As can be seen from table 1, the body weight of the mice during the test did not have significant difference between each dose group and the control group (P > 0.05), indicating that the lactobacillus brevis TR103 did not have significant effect on the body weight of the mice during the test.
TABLE 2
The experimental mice orally administrate the Bifidobacterium breve TR103 strain once a day, and the influence on the first grain defecation time, the number of the defecation granules within 5h, the quality and the water content of the excrement of the constipation model mice is continuously measured after 7 days, and the result is shown in Table 2. Compared with the blank group, the mice in the model group have very significant differences (P < 0.01) in the first defecation time, the number of defecation particles in 5h, the defecation quality and the water content of the excrement, which indicates that the constipation mouse model is established.
Through gastric lavage for 7d, the first defecation time, the defecation quality within 5h and the defecation grain number of mice in each dose group of the Lactobacillus brevis TR103 reach extremely significant levels (P is less than 0.01) compared with those in a model group; the water content of the defecate of the mice in the medium and high dose groups is also obviously improved compared with that in the model group (P < 0.01). And the dosage effect is shown, and with the increase of the gavage dosage, the first defecation time of the mouse, the number of defecation particles in 5h, the defecation quality, the water content of excrement and the like are gradually enhanced.
Sequence listing
<110> biological science and technology Limited of Yiruilan, Nanjing
<120> Bifidobacterium breve and application thereof
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 896
<212> DNA
<213> Bifidobacterium breve (Bifidobacterium breve)
<400> 1
gaggtcggga acgcattcac cgcgacgttg ctgattcgcg attactagcg actccgcctt 60
cacgcagtcg agttgcagac tgcgatccga actgagaccg gttttcaggg atccgctcca 120
gctcgcactg tcgcatcccg ttgtaccggc cattgtagca tgcgtgaagc cctggacgta 180
aggggcatga tgatctgacg tcatccccac cttcctccga gttaaccccg gcggtccccc 240
gtgagttccc ggcacaatcc gctggcaaca cggggcgagg gttgcgctcg ttgcgggact 300
taacccaaca tctcacgaca cgagctgacg acgaccatgc accacctgtg aacccgcccc 360
gaagggaaac cccatctctg ggatcgtcgg gaacatgtca agcccaggta aggttcttcg 420
cgttgcatcg aattaatccg catgctccgc cgcttgtgcg ggcccccgtc aatttctttg 480
agttttagcc ttgcggccgt actccccagg cgggatgctt aacgcgttag ctccgacacg 540
gaacccgtgg aacgggcccc acatccagca tccaccgttt acggcgtgga ctaccagggt 600
atctaatcct gttcgctccc cacgctttcg ctcctcagcg tcagtaacgg cccagagacc 660
tgccttcgcc attggtgttc ttcccgatat ctacacattc caccgttaca ccgggaattc 720
cagtctcccc taccgcactc aagcccgccc gtacccggcg cggatccacc gttaagcgat 780
ggactttcac accggacgcg acgaaccgcc tacgagccct ttacgcccaa taattccgga 840
taacgcttgc accctacgaa ttaccgcggc tgctggcccg cgcggcttta taaaaa 896
Claims (7)
1. Bifidobacterium breve (Bifidobacterium breve) TR103, which is preserved in China center for type culture Collection with the preservation number of CCTCC NO: m2018728, the preservation address is Wuhan university in Wuhan city of Hubei province of the people's republic of China, and the preservation date is 10 months and 31 days in 2018.
2. Bifidobacterium breve (Bifidobacterium breve) (C) as claimed in claim 1Bifidobacterium breve) The large-scale fermentation method of TR103 is characterized in that: the method comprises the following steps:
the components are as follows: aqueous solution, wherein, 2 percent of yeast extract, 1 percent of soybean peptone, 0.5 percent of anhydrous sodium acetate, 0.2 percent of dipotassium phosphate, 0.2 percent of diammonium hydrogen citrate and 800.1 percent of tween-800 are sterilized for 20 minutes at 121 ℃;
and (2) component: an aqueous solution, wherein the glucose anhydrous is 2.3%, the galacto-oligosaccharide is 0.4%, the anhydrous magnesium sulfate is 0.025%, the manganese sulfate monohydrate is 0.02%, and the solution is sterilized at 115 ℃ for 20 minutes;
and (3) component: an aqueous solution, wherein, L-cysteine hydrochloride is 0.1 percent, and the sterilization kettle is sterilized for 20 minutes at the temperature of 121 ℃;
mixing component 1 cooled to below 40 deg.C and component 2 cooled to below 40 deg.C, and adjusting pH to 7.1; inoculating; then adding the component 3; culturing at constant temperature of 37 ℃.
3. Bifidobacterium breve: (Bifidobacterium breve) Application of TR103 in preparing medicine or health product for treating/preventing intestinal mucosa injury.
4. Bifidobacterium breve: (Bifidobacterium breve) Application of TR103 in preparing medicine or health product for preventing and/or treating liver injury caused by alcohol.
5. Bifidobacterium breve: (Bifidobacterium breve) Application of TR103 in preparing medicine or health product for preventing and/or treating constipation.
6. A pharmaceutical composition comprising Bifidobacterium breve (Bifidobacterium breve) ((R))Bifidobacterium breve) TR103, further comprising at least one pharmaceutically acceptable carrier, diluent, excipient or adjuvant.
7. The pharmaceutical composition of claim 6, wherein the pharmaceutical composition is a drug or health product for treating/preventing intestinal mucosal injury in mice, preventing and/or treating liver injury caused by alcohol, and preventing and/or treating constipation; bifidobacterium breve: (A), (B)Bifidobacterium breve) TR103 dose is (0.3-2.0). times.1010CFU/g。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010984015.1A CN111996153B (en) | 2020-09-18 | 2020-09-18 | Bifidobacterium breve and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010984015.1A CN111996153B (en) | 2020-09-18 | 2020-09-18 | Bifidobacterium breve and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111996153A true CN111996153A (en) | 2020-11-27 |
CN111996153B CN111996153B (en) | 2022-02-15 |
Family
ID=73474544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010984015.1A Active CN111996153B (en) | 2020-09-18 | 2020-09-18 | Bifidobacterium breve and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111996153B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112807328A (en) * | 2021-02-26 | 2021-05-18 | 江苏德禧生物科技有限公司 | Application of selenium-rich probiotics in preparation of medicine for treating and/or preventing radiation liver injury |
CN114748514A (en) * | 2022-05-13 | 2022-07-15 | 浙江大学医学院附属邵逸夫医院 | Application of three kinds of bifidobacteria in preventing or treating acute pancreatitis |
CN114774328A (en) * | 2022-05-13 | 2022-07-22 | 江南大学 | Bifidobacterium breve capable of reducing IL-17 and relieving constipation and application thereof |
CN114949007A (en) * | 2022-07-04 | 2022-08-30 | 南昌大学第一附属医院 | Application of bifidobacterium pseudolongum in preparing medicine for preventing and treating pancreatitis |
CN116970530A (en) * | 2023-08-07 | 2023-10-31 | 江苏新申奥生物科技有限公司 | Bifidobacterium breve FPHC4024 for preventing and treating infantile diarrhea and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019211341A1 (en) * | 2018-05-01 | 2019-11-07 | Chr. Hansen A/S | Probiotic bifidobacterium breve strain and compositions comprising said strain |
CN111494431A (en) * | 2020-04-28 | 2020-08-07 | 苏州大学 | Application of probiotics in preparation of preparation for treating liver diseases |
-
2020
- 2020-09-18 CN CN202010984015.1A patent/CN111996153B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019211341A1 (en) * | 2018-05-01 | 2019-11-07 | Chr. Hansen A/S | Probiotic bifidobacterium breve strain and compositions comprising said strain |
CN111494431A (en) * | 2020-04-28 | 2020-08-07 | 苏州大学 | Application of probiotics in preparation of preparation for treating liver diseases |
Non-Patent Citations (2)
Title |
---|
M M TABBERS 等: "Is Bifidobacterium breve effective in the treatment of childhood constipation? results from a pilot study", 《NUTRITION JOURNAL》 * |
XIAOZHU TIAN等: "Bifidobacterium breve ATCC15700 pretreatment prevents alcoholic liver disease through modulating gut microbiota in mice exposed to chronic alcohol intake", 《JOURNAL OF FUNCTIONAL FOODS》 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112807328A (en) * | 2021-02-26 | 2021-05-18 | 江苏德禧生物科技有限公司 | Application of selenium-rich probiotics in preparation of medicine for treating and/or preventing radiation liver injury |
CN112807328B (en) * | 2021-02-26 | 2023-04-11 | 江苏德禧生物科技有限公司 | Application of selenium-rich probiotics in preparation of medicine for treating and/or preventing radiation liver injury |
CN114748514A (en) * | 2022-05-13 | 2022-07-15 | 浙江大学医学院附属邵逸夫医院 | Application of three kinds of bifidobacteria in preventing or treating acute pancreatitis |
CN114774328A (en) * | 2022-05-13 | 2022-07-22 | 江南大学 | Bifidobacterium breve capable of reducing IL-17 and relieving constipation and application thereof |
CN114774328B (en) * | 2022-05-13 | 2023-07-18 | 江南大学 | Bifidobacterium breve capable of down-regulating IL-17 and relieving constipation and application thereof |
CN114949007A (en) * | 2022-07-04 | 2022-08-30 | 南昌大学第一附属医院 | Application of bifidobacterium pseudolongum in preparing medicine for preventing and treating pancreatitis |
CN116970530A (en) * | 2023-08-07 | 2023-10-31 | 江苏新申奥生物科技有限公司 | Bifidobacterium breve FPHC4024 for preventing and treating infantile diarrhea and application thereof |
CN116970530B (en) * | 2023-08-07 | 2024-02-06 | 江苏新申奥生物科技有限公司 | Bifidobacterium breve FPHC4024 for preventing and treating infantile diarrhea and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN111996153B (en) | 2022-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111996153B (en) | Bifidobacterium breve and application thereof | |
TWI241912B (en) | Novel Acid-and bile salt-resistant Lactobacillus isolates having the ability to lower and assimilate cholesterol | |
TWI636133B (en) | A lactobacillus plantarum, composition, culturing method and use of elimination of body fat, reduction of hepatomegaly and/or anti-inflammatory | |
TWI634207B (en) | A lactobacillus plantarum, composition, culturing method and use of decrease uric acid, improvement of allergy and/or decrease blood sugar | |
CN112322527A (en) | Lactobacillus reuteri capable of intervening metabolic syndrome and application thereof | |
CN113403231B (en) | Lactobacillus reuteri CCFM1178 capable of intervening metabolic syndrome and application thereof | |
CN113249280B (en) | Streptococcus thermophilus STN26, bacterium powder and application in uric acid reducing product | |
CN110093287B (en) | Bifidobacterium pseudocatenulatum CCFM1045, composition thereof, fermented food, application, microbial inoculum and preparation method of microbial inoculum | |
CN111011856A (en) | Composition for relieving gastropathy, preparation method thereof and food for relieving gastropathy | |
CN110893193A (en) | Novel application of bifidobacterium lactis BL-99 | |
CN114107134B (en) | Brevibacillus laterosporus and application thereof | |
CN116121154B (en) | Leuconostoc lactis and application thereof | |
TWI636134B (en) | A lactobacillus plantarum, composition, culturing method and use of decrease blood lipids and/or decrease function index | |
KR101940001B1 (en) | Compositions and methods for augmenting kidney function | |
CN116970539B (en) | Lactobacillus murine complex, composition and application thereof | |
CN112029676B (en) | Probiotic composition beneficial to improving immunity and application thereof | |
CN114686405B (en) | Bifidobacterium bifidum with functions of reducing fat, relieving hyperglycemia and regulating intestinal immunity and application thereof | |
CN116024129A (en) | Lactobacillus crispatus capable of co-aggregating with helicobacter pylori and application thereof | |
CN113005066B (en) | Compound bifidobacterium preparation for resisting allergy, increasing immunity, reducing blood sugar and fat and losing weight and preparation method thereof | |
CN112236154A (en) | Composition and application thereof | |
CN114921383A (en) | Probiotic preparation with cholesterol removing function and preparation method thereof | |
CN110892961B (en) | Solid beverage containing bifidobacterium lactis BL-99 and application thereof | |
CN116606761B (en) | Bifidobacterium animalis subspecies BLa19 capable of relieving rheumatoid arthritis and application thereof | |
CN117965391B (en) | Acremonium muciniphilum Amuci-1 and application thereof | |
CN117946949B (en) | Acremonium muciniphilum and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20211115 Address after: 518000 room 1023, 10th floor, East Building, Xinghua building, No. 2018, Shennan Middle Road, Huaqiangbei street, Futian District, Shenzhen, Guangdong Province Applicant after: Shenzhen Chuangxin Medical Technology Co., Ltd Address before: 210000 room 932, building a, phase I, Yangzi science and innovation center, No. 211, pubin Road, Jiangbei new area, high tech Development Zone, Nanjing, Jiangsu Province Applicant before: Nanjing yiruilan Biotechnology Co., Ltd |
|
GR01 | Patent grant | ||
GR01 | Patent grant |